In his recent perspective piece in the journal Science, and in this Q & A, Randy Noelle, PhD, an emeritus professor of microbiology and immunology at Geisel, discusses efforts to develop CD40L antagonists and why they are proving to be powerful autoimmune drugs that have the potential to fundamentally change the way we treat inflammatory diseases.